Limits...
Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.


Sensitivity analysis for this meta-analysis.Abbreviation: CI, confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036562&req=5

f3-ott-9-5771: Sensitivity analysis for this meta-analysis.Abbreviation: CI, confidence interval.

Mentions: The pooled HR showed that decreased expression of miR-133a was significantly associated with unfavorable OS in patients with solid cancers (HR =1.62, 95% CI: 1.16–2.24, P=0.004) (Figure 2). However, obvious heterogeneity (I2=59.3%, P=0.008) was discovered by using a random-effects model. Therefore, sensitivity analysis was performed to assess the stability of the results by successively omitting each study. Results showed the pooled HRs did not vary substantially by excluding any individual study, indicating a better stability of this meta-analysis (Figure 3). Furthermore, a meta-regression was conducted to investigate the potential responsible factors for the heterogeneity. It found that none of these factors, including region, cancer type, cases (as well as the number of patients with follow-up data), maximum follow-up month, tissue preservation, cutoff value, and analysis of variance was contributing to the heterogeneity significance.


Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis
Sensitivity analysis for this meta-analysis.Abbreviation: CI, confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036562&req=5

f3-ott-9-5771: Sensitivity analysis for this meta-analysis.Abbreviation: CI, confidence interval.
Mentions: The pooled HR showed that decreased expression of miR-133a was significantly associated with unfavorable OS in patients with solid cancers (HR =1.62, 95% CI: 1.16–2.24, P=0.004) (Figure 2). However, obvious heterogeneity (I2=59.3%, P=0.008) was discovered by using a random-effects model. Therefore, sensitivity analysis was performed to assess the stability of the results by successively omitting each study. Results showed the pooled HRs did not vary substantially by excluding any individual study, indicating a better stability of this meta-analysis (Figure 3). Furthermore, a meta-regression was conducted to investigate the potential responsible factors for the heterogeneity. It found that none of these factors, including region, cancer type, cases (as well as the number of patients with follow-up data), maximum follow-up month, tissue preservation, cutoff value, and analysis of variance was contributing to the heterogeneity significance.

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.